Agilent Technologies (NYSE:A) Raised to "Strong-Buy" at Rothschild Redb

Key Points

• Agilent Technologies has been upgraded to a "strong-buy" rating by Rothschild Redb, indicating positive outlook and momentum for the stock.
• A total of eight analysts have issued a "buy" rating for Agilent Technologies, contributing to an average target price of $148.69.
• Despite the positive ratings, Agilent shares traded down by 1.4% to $138.89, having a 52-week range between $96.43 and $153.84.

Agilent Technologies (NYSE:A - Get Free Report) was upgraded by equities research analysts at Rothschild Redb to a "strong-buy" rating in a research report issued to clients and investors on Wednesday,Zacks.com reports.

A number of other research analysts have also recently weighed in on A. Robert W. Baird lifted their target price on Agilent Technologies from $141.00 to $142.00 and gave the company an "outperform" rating in a report on Thursday, August 28th. Barclays lifted their target price on Agilent Technologies from $125.00 to $150.00 and gave the company an "equal weight" rating in a report on Thursday, October 2nd. UBS Group upgraded Agilent Technologies from a "neutral" rating to a "buy" rating and lifted their target price for the company from $130.00 to $170.00 in a report on Wednesday. Weiss Ratings restated a "hold (c)" rating on shares of Agilent Technologies in a research note on Wednesday. Finally, Rothschild & Co Redburn assumed coverage on Agilent Technologies in a research note on Wednesday. They set a "buy" rating and a $165.00 price objective on the stock. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and six have given a Hold rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $148.69.

Agilent Technologies Trading Down 1.4%

Shares of A stock traded down $1.92 during mid-day trading on Wednesday, hitting $138.89. 111,555 shares of the company's stock were exchanged, compared to its average volume of 1,933,187. Agilent Technologies has a fifty-two week low of $96.43 and a fifty-two week high of $153.84. The stock has a 50-day simple moving average of $124.07 and a two-hundred day simple moving average of $116.81. The company has a quick ratio of 1.71, a current ratio of 2.25 and a debt-to-equity ratio of 0.53. The stock has a market cap of $39.38 billion, a price-to-earnings ratio of 32.52, a PEG ratio of 4.52 and a beta of 1.26.

Agilent Technologies (NYSE:A - Get Free Report) last posted its quarterly earnings data on Wednesday, August 27th. The medical research company reported $1.37 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.37. Agilent Technologies had a return on equity of 25.51% and a net margin of 17.97%.The business had revenue of $1.74 billion for the quarter, compared to analysts' expectations of $1.67 billion. During the same quarter last year, the firm earned $1.32 earnings per share. The business's revenue was up 10.1% on a year-over-year basis. Agilent Technologies has set its FY 2025 guidance at 5.560-5.590 EPS. Q4 2025 guidance at 1.570-1.600 EPS. Equities analysts expect that Agilent Technologies will post 5.58 EPS for the current fiscal year.

Hedge Funds Weigh In On Agilent Technologies

A number of hedge funds and other institutional investors have recently bought and sold shares of A. Norges Bank acquired a new position in Agilent Technologies in the second quarter valued at approximately $395,088,000. AQR Capital Management LLC boosted its stake in Agilent Technologies by 424.1% in the second quarter. AQR Capital Management LLC now owns 2,041,826 shares of the medical research company's stock valued at $240,956,000 after acquiring an additional 1,652,244 shares during the period. Ameriprise Financial Inc. boosted its stake in Agilent Technologies by 132.2% in the second quarter. Ameriprise Financial Inc. now owns 2,354,111 shares of the medical research company's stock valued at $277,807,000 after acquiring an additional 1,340,161 shares during the period. Massachusetts Financial Services Co. MA boosted its stake in Agilent Technologies by 10.7% in the second quarter. Massachusetts Financial Services Co. MA now owns 13,227,387 shares of the medical research company's stock valued at $1,560,964,000 after acquiring an additional 1,273,994 shares during the period. Finally, Troy Asset Management Ltd boosted its stake in Agilent Technologies by 74.3% in the second quarter. Troy Asset Management Ltd now owns 2,397,820 shares of the medical research company's stock valued at $282,967,000 after acquiring an additional 1,021,865 shares during the period.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.